Organon to file Q3 2026 10-Q with no milestone expense expected
Organon will report Q3 2026 results via Form 10-Q and a same-day 8-K and expects no milestone expense. Earnings calls are suspended during the pending Sun Pharma deal.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to TradingView, citing Organon's press release distributed by BusinessWire, the company will publish its Q3 2026 results in a Form 10-Q. A same-day Form 8-K will include reconciliations of non-GAAP measures.
Organon does not expect any milestone expense in the third quarter. While the acquisition by Sun Pharma is pending, quarterly earnings calls with analysts are not being held.
why it matters
The update is procedural: it confirms the format and timing of disclosure rather than new results. For shareholders, the more important items will be the final figures, any updated guidance and progress on the Sun Pharma deal, which remains the main driver for OGN shares.
market impact
OGN shares: no call means less management commentary; the Sun Pharma deal remains the main driver
tags
instruments
sources
- Organon (OGN) To File Q3 2026 10-Q; No Q3 Milestone Expense Expected — TradingView, 19 October 2026 at 11:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗